| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Tenon Medical, Inc. Common Stock$0.19
0 (-0.1%)
F 2Pipeline Score Tools & Services · Clinical
Market Cap
8.69 M
EPS
-2.06
P/E Ratio
-0.37 $
Value Trade
24.69 K
SEC Financials
Q1 2026Dilution Risk
Revenue
1.38 M
R&D Expenses
662.00 K
Operating CF
-2.96 M
Total Assets
12.84 M
Total Liabilities
10.94 M
Equity
1.90 M
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
4.61 M
Monthly Burn
987.00 K
Runway
2.3 mo
Burn Trend
StableSEC Filing
May 15, 2026
Overview
Volume
373.55 K
52 Week Range
0.64 - 2.48
% held by Insiders
25.81 %
% held by Institutions
2.11 %
Enterprise Value
8.15 M
Total Shares
11.85 M
Short %
3.73 %
Float Shares
9.49 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Tenon Medical, Inc. Common Stock
2Total events
0Upcoming
0Tier-1 (high impact)
2026 – 2026Coverage
Event history 2
TBD
▼Equity OfferingCorporate
Subscribe to view catalyst details
TBD
▼Equity OfferingCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
F2
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 3%
Micro Cap (rank 896 of 923)
Percentile RankTenon Medical, Inc. Common Stock has significant pipeline risk (2/100), but cash runway is a concern.
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TNON
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TNON Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-TNON
Jul 1, 2026WallachBeth Capital Announces Closing of Tenon Medical, Inc. $4.2 Million Public Offering
WallachBeth Capital announced the successful closing of Tenon Medical's $4.2 million public offering. The offering included over 11 million shares and warrants, aimed at funding various corporate initiatives. Proceeds will be utilized for debt repayment, product expansion, and clinical research. The offering was facilitated by WallachBeth Capital as the sole placement agent.
Read more →-TNON
Jun 30, 2026WallachBeth Capital Announces Pricing of Tenon Medical, Inc. $4.2 Million Public Offering
WallachBeth Capital announced that Tenon Medical, Inc. has priced a public offering to raise approximately $4.2 million. The offering includes shares of common stock and accompanying warrants, aimed at supporting various corporate initiatives, including repayment of convertible notes and expansion of its product portfolio. The offering is being conducted under a registration statement filed with the SEC.
Read more →-TNON
May 13, 2026▼ -11.5%on this news
Tenon(R) Medical Reports First Quarter 2026 Financial Results
Tenon Medical reported a substantial increase in its first quarter 2026 financial results, with revenue reaching $1.4 million, a 90% rise compared to the previous year. The gross profit also saw a significant increase of 193%, leading to a gross margin of 68.5%. The company closed a $4.3 million private placement to support its commercial expansion and product development efforts. Despite a net loss of $3.5 million, the company is optimistic about its growth trajectory and plans to continue expanding its surgical offerings.
Read more →-TNON
May 12, 2026Tenon Medical Reports First Quarter 2026 Financial Results ~ First Quarter 2026 Revenue of $1.4 Million, an Increase of Approximately 90% Compared to Prior Year ~ ~ First Quarter Gross Profit of $0.9 Million, an Increase
Tenon Medical reported strong financial results for the first quarter of 2026, with a revenue of $1.4 million, up nearly 90% from the previous year. Gross profit also saw a significant increase of approximately 193%, leading to a gross margin improvement to 68.5%. The company focused on expanding its surgical systems and increasing surgeon engagement. However, while revenues grew, operating expenses also increased, leading to a net loss of $3.5 million.
Read more →-TNON
Mar 20, 2026Tenon(R) Medical Reports Fourth Quarter and Full Year 2025 Financial Results
Tenon Medical reported significant financial growth for Q4 and full year 2025, with revenues reaching $1.5 million in Q4, a 92% increase year-over-year. The company also achieved FDA clearance for its SImmetry+ SI Joint Fusion System, enhancing its market position. Despite a net loss of $2.8 million in Q4, the company is optimistic about future growth driven by increased surgeon adoption and a strengthened balance sheet.
Read more →-TNON
Mar 19, 2026Tenon Medical Reports Fourth Quarter and Full Year 2025 Financial Results ~ Fourth Quarter 2025 Revenue of $1.5 Million, a 92% Increase Compared to Prior Year ~ ~ Record Full Year 2025 Revenue of $3.9 Million, a 20% Incr
Tenon Medical reported significant financial results for the fourth quarter and full year of 2025, with Q4 revenue reaching $1.5 million, a 92% increase from 2024. The full year revenue also marked a record at $3.9 million, up 20% year-over-year, primarily driven by increased surgical procedures. The company received FDA clearance for its new SImmetry + SI joint fusion system and has begun procedures, enhancing its competitive position. However, the company reported a net loss in Q4, although showing improvement compared to previous losses.
Read more →-TNON
Mar 12, 2026Tenon Medical Announces Closing of Private Placement of Senior Convertible Notes Offering for Gross Proceeds of $ 4.3 Million LOS GATOS, CA / ACCESS Newswire /
Tenon Medical, Inc. has announced the closing of a private placement of senior convertible notes, generating gross proceeds of $4.3 million. The financing aims to support various initiatives, including commercial expansion and clinical studies. The notes have a maturity date set for September 11, 2026, and can be converted into shares of common stock at a predefined price. This move reflects Tenon's strategic efforts to enhance its position in the medical device market, particularly in treating sacro-pelvic disorders.
Read more →-TNON
Feb 18, 2026▲ +5.3%on this news
Tenon(R) Medical Strengthens Intellectual Property Portfolio with Strategic Patent Expansion
Tenon Medical, Inc. has announced a strategic expansion of its U.S. intellectual property portfolio, receiving Notices of Allowance for multiple patent applications. This expansion builds on ten patents issued in 2025 and strengthens protection for its Catamaran SI Joint Fusion System. The company aims to enhance its competitive position and drive long-term growth through continued innovation and diversification of its patent assets.
Read more →-TNON
Feb 5, 2026Tenon Medical, Inc. Sets Date for Fourth Quarter and Full Year 2025 Earnings, Reaffirms Expected Revenues
Tenon Medical, Inc. has announced its plans to release financial results for the fourth quarter and full year 2025 on March 19, 2026. The company anticipates a revenue of $1.45 to $1.48 million for Q4 2025, reflecting a significant growth of approximately 90% compared to the previous year. Additionally, the full year revenue is expected to be between $3.91 to $3.94 million, indicating a 20% year-over-year increase.
Read more →-TNON
Jan 29, 2026Tenon(R) Medical Issues Shareholder Letter and Provides Preliminary Revenue for the Fourth Quarter and Full Year 2025
Tenon Medical reported strong preliminary revenue growth for Q4 and full year 2025, with Q4 revenue estimated at $1.45 to $1.48 million, reflecting a 90% increase year-over-year. The company highlighted significant milestones, including the acquisition of SiVantage technologies and FDA clearance for its Catamaran SI Joint Fusion System. Looking ahead, Tenon aims to leverage its expanded product portfolio for sustained growth in 2026.
Read more →-TNON
Nov 11, 2025Tenon Medical Announces Pricing of At-The-Market PIPE Financing ~ Strategically Placed PIPE With Industry Supportive Investor Cohort ~ LOS GATOS, CA / ACCESS Newswire /
Tenon Medical, Inc. has announced the pricing of an at-the-market private investment in public equity (PIPE) financing, garnering $2.85 million in gross proceeds. The PIPE is backed by several accredited investors, indicating strong support from strategic industry partners. The company plans to use the funds for working capital, expansion of commercial operations, and advancement of clinical studies, positioning itself for future growth in sacro-pelvic disorder treatments.
Read more →-TNON
Aug 1, 2025▲ +43.1%on this news
Tenon Medical Expands Sacro-Pelvic Fusion Portfolio with Strategic Asset Acquisition ~ SiVantage Portfolio Acquisition Enhances Tenon's Sacroiliac Joint Fusion Capabilities with a Unique Multi-Product, Multi-Approach Sol
Tenon Medical, Inc. has announced a strategic asset acquisition from SiVantage, enhancing its capabilities in sacro-pelvic fusion technology. This acquisition includes SiVantage's SImmetry and SImmetry+ technologies, which will allow for customized treatment plans for patients with sacroiliac joint disorders. The deal positions Tenon Medical as a leader in the rapidly evolving sacro pelvic fusion market, focusing on innovative solutions backed by clinical data.
Read more →-TNON
Mar 25, 2025▲ +283.4%on this news
Tenon Medical, Inc. Announces a $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules LOS GATOS, CA / ACCESSWIRE /
Tenon Medical, Inc. has announced a $2.5 million registered direct offering and a concurrent private placement priced at-the-market. The company will issue 1,271,500 shares of common stock and warrants to an institutional investor, with proceeds intended for working capital and general corporate purposes. The closing of the offering is expected by March 27, 2025, pending customary conditions. Tenon is known for its innovative approach to treating sacroiliac joint disorders.
Read more →-TNON
Mar 25, 2025▲ +283.4%on this news
Tenon Medical, Inc. Announces a Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules LOS GATOS, CA / ACCESSWIRE /
Tenon Medical, Inc. has announced a registered direct offering and a concurrent private placement with a single institutional investor, targeting the issuance of 733,500 shares at $2.00 each. The expected gross proceeds of around $1.5 million will be allocated towards working capital and corporate purposes. The completion of the offering is anticipated on or about March 26, 2025, pending customary closing conditions. This initiative follows the company's recent focus on the Catamaran SI Joint Fusion System for treating sacroiliac joint disorders.
Read more →-TNON
Sep 12, 2024▲ +43.8%on this news· ran to +147% by day 1
Tenon Medical, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules Thursday, 12 September 2024 09:30 PM LOS GATOS, CA / ACCESSWIRE /
Tenon Medical, Inc. has announced a public offering priced at $4.5 million under Nasdaq rules. This offering involves the sale of up to 1,222,850 shares and warrants at $3.68 per share, expected to close by September 16, 2024. The funds will be allocated towards commercial activities and working capital, enhancing the company’s operations in sacroiliac joint disorders. The offering's regulatory aspects were confirmed by the SEC's approval of the registration statement.
Read more →-TNON
Aug 27, 2024▲ +5.6%on this news
Tenon Medical Appoints Medical Device Veteran, Kevin Williamson, Chief Financial Officer Los Gatos, CA
Tenon Medical, Inc. has appointed Kevin Williamson as its new Chief Financial Officer, succeeding Steve Van Dick. Williamson brings a wealth of experience from his previous positions in medical device companies, specifically in finance and operational oversight. His appointment aligns with key milestones for Tenon, including the full enrollment of a clinical trial for their Catamaran SI Joint Fusion System. This strategic leadership change is anticipated to help the company advance its market objectives and growth plans in addressing sacroiliac joint disorders.
Read more →-TNON
Mar 28, 2024▲ +5.5%on this news
Experienced Medical Devices Industry Executive Joins Tenon's Board of Directors LOS GATOS, CA / ACCESSWIRE /
Tenon Medical, Inc. has appointed Kristine Jacques to its Board of Directors, effective immediately. With over 35 years of experience in the medical devices industry, Jacques is expected to contribute valuable insights aimed at advancing Tenon's commercialization strategy for its Catamaran SI Joint Fusion System. The appointment adds depth to the board, which now consists of seven members, including four independent directors. Jacques's expertise in product management and market strategies could be pivotal as the company navigates toward growth and expansion in its offerings.
Read more →-TNON
Mar 12, 2024Tenon Medical Reports Fourth Quarter and Full Year 2023 Financial Results ~ Fourth Quarter 2023 Revenue Increased 192% Year-Over-Year ~ ~ Full Year 2023 Revenue Increased 324% Year-Over-Year ~ ~ Surgical Procedures Incre
Tenon Medical reported impressive financial results for the fourth quarter and full year of 2023, with Q4 revenue climbing by 192% year-over-year to reach $808,000. Full year revenue also saw a substantial increase of 324%, amounting to $2.9 million, driven by a 312% jump in surgical procedures using the Catamaran SI Joint Fusion System. The company achieved positive gross profit margins for three consecutive quarters, reflecting strong operational progress. Despite these successes, net losses were reported at $15.6 million for the year, with expectations of additional losses in the near future.
Read more →-TNON
Feb 21, 2024Tenon Medical, Inc. Issues Approximately $3.85 Million in Series A Preferred Stock ~ Raises approximately $2.6 Million in gross proceeds ~ ~ Retires $1.25 Million in secured debt ~ LOS GATOS, CA / ACCESSWIRE /
Tenon Medical, Inc. has successfully closed a private placement of approximately $2.6 million through the issuance of Series A Preferred Stock and warrants. The company plans to use these funds for growth investments, working capital, and general corporate purposes. Additionally, Tenon announced the retirement of $1.25 million in secured debt via the exchange of notes for preferred stock. The company's innovative Catamaran SI Joint Fusion System continues to expand its market opportunities.
Read more →-TNON
Jan 10, 2024Tenon Medical, Inc. Announces Second Adjournment of Special Meeting of Stockholders Meeting adjourned to Tuesday
Tenon Medical, Inc. announced the adjournment of its Special Meeting of Stockholders to January 30, 2024, to allow for additional time to gather votes on Proposal 2. The proposal involves amending the Certificate of Incorporation and requires a majority vote from the outstanding shares. Tenon's Board recommends support for the proposal, emphasizing that a lack of response is viewed as opposition. Stockholders remain eligible to vote regardless of whether they have sold their shares since the record date established on November 9, 2023.
Read more →-TNON
Dec 26, 2023▼ -8.8%on this news
Tenon Medical, Inc. Announces Adjournment of Special Meeting of Stockholders Tenon Medical, Inc. Meeting adjourned to Monday
Tenon Medical, Inc. has announced the adjournment of its Special Meeting of Stockholders originally scheduled for December 21, 2023, to January 8, 2024. This delay is intended to give stockholders additional time to cast their votes regarding Proposal 2, which involves an amendment to the Certificate of Incorporation. The Board of Directors is urging stockholders to vote in favor of the proposal, emphasizing that failure to participate may be viewed as opposition. The record date for voting remains November 9, 2023, allowing stockholders who sold shares after this date to still vote.
Read more →-TNON
Nov 1, 2023▼ -38.9%on this news
Tenon Medical Announces 1:10 Reverse Split LOS GATOS, CA / ACCESSWIRE /
Tenon Medical, Inc. has announced a 1:10 reverse stock split, set to take effect at 12:01 Eastern Time on November 2, 2023. This decision aims to increase the per-share market price to comply with Nasdaq's minimum requirement of $1.00. Shareholders had previously approved this split during the annual meeting on September 13, 2023. The reverse split will adjust the number of outstanding shares, consolidating ten shares into one without requiring action from stockholders holding their shares through various channels.
Read more →-TNON
Jun 14, 2023▼ -52.9%on this news
Tenon Medical Announces Pricing of $5.6 Million Public Offering
Tenon Medical, Inc. announced the pricing of its public offering, targeting $5.6 million from the sale of 10,000,000 units. Each unit consists of one share of common stock and two warrants exercisable at $0.56 each. The offering is set to close on June 16, 2023, contingent on customary closing conditions. This launch supports their innovative Catamaran SI Joint Fusion System aimed at treating sacroiliac joint disorders.
Read more →-TNON
Oct 11, 2022Tenon Medical Accelerates Commercial Scale with Own Infrastructure to Support Top Line Growth, Terminates National Distribution Agreement for Company's Catamaran SI Joint Fusion System ~ Tenon reaches amicable terminatio
Tenon Medical Accelerates Commercial Scale with Own Infrastructure to Support Top Line Growth, Terminates National Distribution Agreement for Company's Catamaran SI Joint ~ Tenon reaches amicable termination with exclusive distributor partner, SpineSource ~ ~ SpineSource to s
Read more →-TNON
Jun 7, 2022Tenon Medical, Inc. Reports First Quarter 2022 Financial Results ~ Closes $16 Million IPO and Commences Trading on the Nasdaq ~ Los Gatos, CA
Tenon Medical, Inc. Reports First Quarter 2022 Financial Results ~ Closes $16 Million IPO and Commences Trading on the Nasdaq ~ Los Gatos, CA, June 7, 2022 - ("Tenon Medical" or the "Company"), a medical device company that has developed a proprietary, U.S. Food and Drug Admin
Read more →-TNON
May 31, 2022Investor Presentation June 2022 2 Safe Harbor This presentation contains "forward - looking statements," which are statements related to events, results, activities or developments that Tenon Medical expects, believes or
Investor Presentation June 2022 2 Safe Harbor This presentation contains "forward - looking statements," which are statements related to events, results, activities or developments that Tenon Medical expects, believes or anticipates will or may occur in the future . Forward - lo
Read more →-TNON
Apr 26, 2022Tenon Medical, Inc. Announces Pricing of $16 Million Initial Public Offering Los Gatos, CA
Tenon Medical, Inc. Announces Pricing of $16 Million Initial Public Offering Los Gatos, CA, April 26, 2022 - Tenon Medical, Inc. ("Tenon" or the "Company"), a medical device company that has developed a proprietary, U.S. Food and Drug Administration ("FDA") cleared surgical impl
Read more →Competitive Position
How TNON ranks across every disease it competes inCompetitive Position is a premium feature
See how TNON ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial